Imatinib Medicopharm

Imatinib, the active ingredient in Imatinib Medicopharm, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Imatinib Medicopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib Medicopharm targets BCR‑ABL driven malignancies, providing disease control in specific leukemias.

Chronic Myeloid Leukemia (chronic phase): reduces leukemic cell proliferation and achieves disease control. Accelerated phase Chronic Myeloid Leukemia: slows disease progression and improves hematologic response. Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia: induces remission by targeting BCR‑ABL positive blasts.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting - Diarrhea or abdominal discomfort - Peripheral edema - Muscle cramps or joint pain - Rash or mild skin irritation - Fatigue or weakness

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Severe neutropenia or thrombocytopenia - Cardiac failure or reduced left‑ventricular function - Severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis) - Pulmonary arterial hypertension - Tumor lysis syndrome in high‑risk patients

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly.

Monitor blood counts: perform complete blood count at baseline and periodically. Assess liver function: check hepatic enzymes before treatment and during therapy. Evaluate cardiac status: perform ECG or echocardiogram in patients with cardiac risk factors. Avoid use in patients with known hypersensitivity to imatinib or its excipients. Use caution in renal impairment: adjust monitoring frequency as needed. Store at below 25°C: keep in the original pack, protect from moisture.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise imatinib levels. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Concomitant use with other BCR‑ABL TKIs: increases risk of overlapping toxicities.

Moderate Interactions (Monitor Closely): - Warfarin: imatinib can enhance anticoagulant effect; monitor INR. - Diuretics (e.g., furosemide): may increase risk of electrolyte disturbances. - Other oral antineoplastic agents: assess for additive myelosuppression.